Patients who receive alfuzosin as treatment for benign prostatic hyperplasia (BPH) experience improvements in sexual function as well lower urinary tract symptoms (LUTS), a South Korean study suggests.
In a study of 148 BPH patients with LUTS treated with alfuzosin 10 mg once daily for 24 weeks, investigators evaluated sexual function using the Male Sexual Health Questionnaire (MSHQ) and the International Index of Erectile Function (IIEF).
Continue Reading
At study end point (week 24), subjects showed significant improvement in total MSHQ score and MSHQ ejaculatory scores compared with baseline, as well as significant improvement in IIEF score.
Enjoying our content?
Thanks for visiting Renal & Urology News. We hope you’re enjoying the latest clinical news, full-length features, case studies, and more.
You’ve viewed {{metering-count}} of {{metering-total}} articles this month. If you wish to read unlimited content, please log in or register below. Registration is free.
{{login-button}} {{register-button}}
Log in to continue reading this article.
Don’t miss out on today’s top content on Renal & Urology News. Register for free and gain unlimited access to:
- Clinical News, with personalized daily picks for you
- Case Studies
- Conference Coverage
- Full-Length Features
- Drug Monographs
- And More
{{login-button}} {{register-button}}
Want to read more?
Please login or register first to view this content.